<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="lpl" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">lpl</book-part-id>
      <title-group>
        <title>Familial Lipoprotein Lipase Deficiency</title>
        <alt-title alt-title-type="alt-title">Synonym: Familial LPL Deficiency</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Burnett</surname>
            <given-names>John R</given-names>
          </name>
          <degrees>MB ChB, MD, PhD, FRCPA</degrees>
          <xref ref-type="aff" rid="lpl.Tc.aff1"/>
          <xref ref-type="aff" rid="lpl.Tc.aff2"/>
          <email>john.burnett@health.wa.gov.au</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hooper</surname>
            <given-names>Amanda J</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="lpl.Tc.aff1"/>
          <xref ref-type="aff" rid="lpl.Tc.aff2"/>
          <email>amanda.hooper@health.wa.gov.au</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hegele</surname>
            <given-names>Robert A</given-names>
          </name>
          <degrees>MD, FRCPC, FACP</degrees>
          <xref ref-type="aff" rid="lpl.Tc.aff3"/>
          <email>hegele@robarts.ca</email>
        </contrib>
      </contrib-group>
      <aff id="lpl.Tc.aff1">Department of Clinical Biochemistry<break/>Royal Perth Hospital &#x00026; Fiona Stanley Hospital Network<break/>PathWest Laboratory Medicine</aff>
      <aff id="lpl.Tc.aff2">School of Medicine<break/>Faculty of Health &#x00026; Medical Sciences<break/>University of Western Australia<break/>Perth, Australia</aff>
      <aff id="lpl.Tc.aff3">Departments of Medicine and Biochemistry<break/>Schulich School of Medicine and Robarts Research Institute<break/>Western University<break/>London, Ontario, Canada</aff>
      <pub-history>
        <date date-type="created">
          <day>12</day>
          <month>10</month>
          <year>1999</year>
        </date>
        <date date-type="updated">
          <day>22</day>
          <month>6</month>
          <year>2017</year>
        </date>
        <date date-type="revised">
          <day>1</day>
          <month>10</month>
          <year>2007</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="hi" document-type="chapter">Familial Hyperinsulinism</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="fmf" document-type="chapter">Familial Mediterranean Fever</related-object>
      <abstract id="lpl.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Familial lipoprotein lipase (LPL) deficiency usually presents in childhood and is characterized by very severe hypertriglyceridemia with episodes of abdominal pain, recurrent acute pancreatitis, eruptive cutaneous xanthomata, and hepatosplenomegaly. Clearance of chylomicrons from the plasma is impaired, causing triglycerides to accumulate in plasma and the plasma to have a milky (lactescent or lipemic) appearance. Symptoms usually resolve with restriction of total dietary fat to &#x02264;20 g/day.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of LPL deficiency is established in a proband by the identification of biallelic pathogenic variants in <italic toggle="yes">LPL</italic> on molecular genetic testing.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Treatment is based on medical nutrition therapy to maintain plasma triglyceride concentration below 1000 mg/dL. Maintenance of triglyceride levels below 2000 mg/dL prevents recurrent abdominal pain. Restriction of dietary fat to &#x02264;20 g/day or 15% of a total energy intake is usually sufficient to reduce plasma triglyceride concentration and to keep the individual with familial LPL deficiency free of symptoms. An acute pancreatitis episode is treated with standard care.</p>
          <p><italic toggle="yes">Prevention of secondary complications</italic>: Prevention of recurrent acute pancreatitis decreases the risk of developing diabetes mellitus.</p>
          <p><italic toggle="yes">Surveillance</italic>: Monitoring of plasma triglycerides.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Agents known to increase endogenous triglyceride concentration such as alcohol, oral estrogens, diuretics, isotretinoin, glucocorticoids, selective serotonin reuptake inhibitors, and beta-adrenergic blocking agents; fish oil supplements are contraindicated because they contribute to chylomicron levels.</p>
          <p><italic toggle="yes">Pregnancy management</italic>: For pregnant women with LPL deficiency, extreme dietary fat restriction to &#x0003c;2 g/day during the second and third trimesters of pregnancy with close monitoring of plasma triglyceride concentration is recommended.</p>
          <p><italic toggle="yes">Other</italic>: The lipid-lowering drugs that are used to treat other disorders of lipid metabolism are not effective in individuals with familial LPL deficiency.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Familial LPL deficiency is inherited in an autosomal recessive manner. Each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="lpl.Diagnosis">
        <title>Diagnosis</title>
        <sec id="lpl.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Familial lipoprotein lipase (LPL) deficiency <bold>should be suspected</bold> in individuals (particularly those age &#x0003c;40 years) with the following clinical and supportive laboratory findings.</p>
          <p>
            <bold>Clinical findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Recurrent acute pancreatitis</p>
            </list-item>
            <list-item>
              <p>Eruptive cutaneous xanthomata</p>
            </list-item>
            <list-item>
              <p>Hepatosplenomegaly</p>
            </list-item>
          </list>
          <p>
            <bold>Supportive laboratory findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Impaired clearance of chylomicrons from plasma causing the plasma to have a milky (lactescent or lipemic) appearance</p>
            </list-item>
            <list-item>
              <p>Plasma triglyceride concentrations greater than 2000 mg/dL in the untreated state, regardless of fasting status</p>
            </list-item>
          </list>
        </sec>
        <sec id="lpl.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of LPL deficiency <bold>is established</bold> in a proband by the identification of biallelic pathogenic variants in <italic toggle="yes">LPL</italic> on molecular genetic testing (see <xref ref-type="table" rid="lpl.T.molecular_genetic_testing_used_in">Table 1</xref>).</p>
          <p>A consensus diagnostic algorithm has been published [<xref ref-type="bibr" rid="lpl.REF.stroes.2017.1">Stroes et al 2017</xref>] (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S1567568816300502">Figure 3</ext-link>).</p>
          <p>Molecular genetic testing approaches can include <bold>single-gene testing</bold> or use of a <bold>multi-gene panel</bold>:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">LPL</italic> is performed first and followed by gene-targeted deletion/duplication analysis if only one or no pathogenic variant is found.</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">LPL</italic> and other genes of interest for the chylomicronemia syndrome (see <xref ref-type="sec" rid="lpl.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this <italic toggle="yes">GeneReview</italic>; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of the condition at the most reasonable cost. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing based tests.</p>
              <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
            </list-item>
          </list>
          <table-wrap id="lpl.T.molecular_genetic_testing_used_in" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in Familial Lipoprotein Lipase Deficiency</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_lpl.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_lpl.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_lpl.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_lpl.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">LPL</italic>
                  </td>
                  <td headers="hd_h_lpl.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_lpl.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">~97%&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_lpl.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_lpl.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">~3%&#x000a0;<sup>6</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="lpl.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="lpl" object-id="lpl.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="lpl.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="lpl.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="lpl.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="lpl.TF.1.4">
                <label>4. </label>
                <p><xref ref-type="bibr" rid="lpl.REF.brunzell.2001">Brunzell &#x00026; Deeb [2001]</xref>, <xref ref-type="bibr" rid="lpl.REF.gilbert.2001.25">Gilbert et al [2001]</xref></p>
              </fn>
              <fn id="lpl.TF.1.5">
                <label>5. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="lpl.TF.1.6">
                <label>6. </label>
                <p>
                  <xref ref-type="bibr" rid="lpl.REF.brunzell.2001">Brunzell &#x00026; Deeb [2001]</xref>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Measurement of lipoprotein lipase enzyme activity.</bold> Affected individuals have low or absent LPL enzyme activity in an assay system that contains either normal plasma or apolipoprotein C-II (apoC-II; a cofactor of LPL) and excludes hepatic lipase (HL). This assay is not routinely available and is generally only performed at specialist centers.</p>
          <list list-type="bullet">
            <list-item>
              <p>LPL enzyme activity can be assayed in plasma taken ten minutes following intravenous administration of heparin (60 U/kg body weight). The absence of LPL enzyme activity in postheparin plasma is diagnostic of familial LPL deficiency.</p>
            </list-item>
            <list-item>
              <p>LPL enzyme activity may be assayed directly in biopsies of adipose tissue.</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="lpl.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="lpl.Clinical_Description">
          <title>Clinical Description</title>
          <p>Familial lipoprotein lipase (LPL) deficiency usually presents in childhood with episodes of abdominal pain, recurrent acute pancreatitis, eruptive cutaneous xanthomata, and hepatosplenomegaly. Males and females are affected equally.</p>
          <p>Approximately 25% of affected children develop symptoms before age one year and the majority develop symptoms before age ten years; however, some individuals present for the first time during pregnancy. The severity of symptoms correlates with the degree of chylomicronemia. Chylomicrons are large triglyceride-rich lipoprotein particles that appear in the circulation shortly after the ingestion of dietary fat; normally, they are cleared from plasma after an overnight fast. The degree of chylomicronemia in LPL deficiency varies by dietary fat intake.</p>
          <p>The abdominal pain, which can vary from mildly bothersome to incapacitating, is usually mid-epigastric with radiation to the back. It may be diffuse and mimic an acute abdomen, often leading to unnecessary abdominal exploratory surgery. The pain probably results from chylomicronemia leading to pancreatitis.</p>
          <p><xref ref-type="bibr" rid="lpl.REF.kawashiri.2005.6541">Kawashiri et al [2005]</xref> reported that individuals with LPL deficiency can lead a fairly normal life on a diet very low in total fat content. The secondary complications of pancreatitis &#x02013; diabetes mellitus, steatorrhea, and pancreatic calcification &#x02013; are unusual in individuals with familial LPL deficiency and rarely occur before middle age. Pancreatitis in LPL deficiency may rarely be associated with total pancreatic necrosis and death.</p>
          <p>About 50% of individuals with familial LPL deficiency have eruptive xanthomas, small yellow papules localized over the trunk, buttocks, knees, and extensor surfaces of the arms. Xanthomas are deposits of lipid in the skin that result from the extravascular phagocytosis of chylomicrons by macrophages. They can appear rapidly when plasma triglyceride concentration exceeds 2000 mg/dL and can sometimes regress if plasma triglyceride is normalized.</p>
          <p>Xanthomas may become generalized. As a single lesion, they may be several millimeters in diameter; rarely, they may coalesce into plaques. They are usually not tender unless they occur at a site susceptible to repeated abrasion.</p>
          <p>Hepatomegaly and splenomegaly often occur when plasma triglyceride concentrations are markedly increased. The organomegaly results from triglyceride uptake by macrophages, which become foam cells.</p>
          <p>When triglyceride concentrations exceed 4000 mg/dL, the retinal arterioles and venules, and often the fundus itself, develop a pale pink color ("lipemia retinalis"), caused by light scattering by large chylomicrons. This coloration is reversible and vision is not affected.</p>
          <p>Reversible neuropsychiatric findings, including mild dementia, depression, and memory loss, have also been reported with chylomicronemia [<xref ref-type="bibr" rid="lpl.REF.heilman.1974.67">Heilman &#x00026; Fisher 1974</xref>, <xref ref-type="bibr" rid="lpl.REF.chait.1981.343">Chait et al 1981</xref>].</p>
        </sec>
        <sec id="lpl.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>As most pathogenic <italic toggle="yes">LPL</italic> variants have been reported in individual case reports or small case series, reliable systematic correlation of genotype-phenotype relationships is challenging. There are no known genotype-phenotype correlations.</p>
        </sec>
        <sec id="lpl.Nomenclature">
          <title>Nomenclature</title>
          <p>Familial LPL deficiency is the most common form of the familial chylomicronemia syndrome, which was formerly known as "type 1 hyperlipoproteinemia."</p>
        </sec>
        <sec id="lpl.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of familial LPL deficiency is approximately one in 1,000,000 in the general US population.</p>
          <p>The disease has been described in all races. The prevalence is much higher in some areas of Quebec, Canada as a result of a founder effect.</p>
          <p>Consanguinity is observed in some families with familial LPL deficiency caused by homozygous pathogenic <italic toggle="yes">LPL</italic> variants.</p>
        </sec>
      </sec>
      <sec id="lpl.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">LPL</italic>.</p>
        <p><bold>Mild lipid abnormalities not associated with familial LPL deficiency</bold> have been reported with common variants of <italic toggle="yes">LPL</italic>, such as the p.Asn291Ser allele. The p.Asn291Ser allele does not appear to have a <bold>major</bold> effect on plasma lipid concentration or on risk for coronary disease in the general population; however, it may be associated with hypertriglyceridemia in the presence of the <italic toggle="yes">APOE</italic> E2 allele, diabetes mellitus, familial combined hyperlipidemia, hepatic lipase (HL) deficiency, and <related-object link-type="booklink" source-id="gene" document-id="gsd1" document-type="chapter">glycogen storage disease type Ib</related-object>. It is possible that the association of the p.Asn291Ser allele with these disorders is only a reflection of the relatively high frequency of this allele in the general population. Nonetheless, the allele likely predisposes to mild hypertriglyceridemia, but is insufficient in the absence of a secondary factor to cause more severe hypertriglyceridemia.</p>
      </sec>
      <sec id="lpl.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Familial lipoprotein lipase (LPL) deficiency should be considered in young persons with the chylomicronemia syndrome, defined as abdominal pain, eruptive xanthomata, plasma triglyceride concentrations greater than 2000 mg/dL, and fasting lipemic plasma. However, the majority of individuals with chylomicronemia and plasma triglyceride concentration greater than 2000 mg/dL do not have familial LPL deficiency; rather, they have one of the more common genetic disorders of triglyceride metabolism (i.e., familial combined hyperlipidemia and monogenic familial hypertriglyceridemia). Hypertriglyceridemia can also be polygenic, due to both heterozygous rare large-effect variants and accumulations of common rare small-effect variants in several genes and loci [<xref ref-type="bibr" rid="lpl.REF.hegele.2014.655">Hegele et al 2014</xref>]. With such genetic predisposition, clinical expression of chylomicronemia typically requires the presence of secondary, non-genetic factors [<xref ref-type="bibr" rid="lpl.REF.brunzell.2001">Brunzell &#x00026; Deeb 2001</xref>].</p>
        <p>Secondary causes of hypertriglyceridemia include: diabetes mellitus; paraproteinemia and lymphoproliferative disorders; use of alcohol; and therapy with estrogen, glucocorticoids, selective serotonin reuptake inhibitors, atypical antipsychotic agents, isotretinoin, or certain antihypertensive agents. In one series of 123 individuals evaluated for marked hypertriglyceridemia, 110 had an acquired cause of hypertriglyceridemia combined with a common genetic form of hypertriglyceridemia, five had familial LPL deficiency, five had other rare genetic forms of hypertriglyceridemia, and three had an unknown cause [<xref ref-type="bibr" rid="lpl.REF.chait.1983.209">Chait &#x00026; Brunzell 1983</xref>].</p>
        <p>Other than LPL deficiency, the chylomicronemia syndrome may be caused by biallelic pathogenic variants in apolipoprotein C-II (<italic toggle="yes">APOC2</italic>), apolipoprotein A-V (<italic toggle="yes">APOA5</italic>), lipase maturation factor 1 (<italic toggle="yes">LMF1</italic>) or <italic toggle="yes">GPIHBP1</italic> (see <xref ref-type="table" rid="lpl.T.genetic_causes_of_primary_monogeni">Table 2</xref>).</p>
        <table-wrap id="lpl.T.genetic_causes_of_primary_monogeni" orientation="portrait" position="anchor">
          <label>Table 2. </label>
          <caption>
            <p>Genetic Causes of Primary Monogenic Chylomicronemia</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene (Gene Product)</th>
                <th id="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Homozygote Prevalence</th>
                <th id="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene Product Function</th>
                <th id="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Clinical Features</th>
                <th id="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Molecular Features</th>
                <th id="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_6" valign="middle" align="left" scope="col" rowspan="1" colspan="1">% of Monogenic Variants</th>
                <th id="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_7" valign="middle" align="left" scope="col" rowspan="1" colspan="1">References</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">LPL</italic><break/>(LPL)</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">~1 per million individuals <sup>1</sup></td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Hydrolysis of triglycerides &#x00026; peripheral uptake of FFA</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Severe chylomicronemia in infancy or childhood</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Severely reduced or absent LPL enzyme activity</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">95.0</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_7" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="lpl.REF.murthy.1996.101">Murthy et al [1996]</xref>, <xref ref-type="bibr" rid="lpl.REF.jap.2003.122">Jap et al [2003]</xref>, <xref ref-type="bibr" rid="lpl.REF.gotoda.2012.1">Gotoda et al [2012]</xref>, <xref ref-type="bibr" rid="lpl.REF.mart_ncampos.2014.61">Mart&#x000ed;n-Campos et al [2014]</xref></td>
              </tr>
              <tr>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">APOC2</italic> (apoC-II)</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">10 families reported</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Required cofactor of LPL</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Severe chylomicronemia in childhood or adolescence</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Absent or nonfunctional apoC-II</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">2.0</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_7" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="lpl.REF.gotoda.2012.1">Gotoda et al [2012]</xref>, <xref ref-type="bibr" rid="lpl.REF.okubo.2015.148">Okubo et al [2015]</xref></td>
              </tr>
              <tr>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">GPIHBP1</italic> (GPI-HBP1)</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">10 families reported</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Stabilizes binding of chylomicrons near LPL; supports lipolysis</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Chylomicronemia in late adulthood</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Absent or defective GPI-HBP1</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">2.0</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_7" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="lpl.REF.beigneux.2009.956">Beigneux et al 2009</xref>, <xref ref-type="bibr" rid="lpl.REF.gin.2012.2961">Gin et al [2012]</xref></td>
              </tr>
              <tr>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">APOA5</italic> (apoA-V)</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Three families reported</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Enhancer of LPL activity</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Chylomicronemia in late adulthood</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Absent or defective apoA-V</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">0.6</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_7" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="lpl.REF.calandra.2006.122">Calandra et al [2006]</xref>, <xref ref-type="bibr" rid="lpl.REF.nilsson.2011.15">Nilsson et al [2011]</xref></td>
              </tr>
              <tr>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">LMF1</italic> (LMF1)</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Two families reported</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Chaperone molecule required for proper LPL folding and/or expression</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Chylomicronemia in late adulthood</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Absent or defective LMF1</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">0.4</td>
                <td headers="hd_h_lpl.T.genetic_causes_of_primary_monogeni_1_1_1_7" valign="middle" align="left" rowspan="1" colspan="1">
                  <xref ref-type="bibr" rid="lpl.REF.p_terfy.2012.790">P&#x000e9;terfy [2012]</xref>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>from <xref ref-type="bibr" rid="lpl.REF.brahm.2015.352">Brahm &#x00026; Hegele [2015]</xref>; reprinted by permission of Macmillan Publishers, Ltd.</p>
            </fn>
            <fn>
              <p>apoA-V = apolipoprotein A-V</p>
            </fn>
            <fn>
              <p>apoC-II = apolipoprotein C-II</p>
            </fn>
            <fn>
              <p>FFA = free fatty acid</p>
            </fn>
            <fn>
              <p>GPI-HBP1 = glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1</p>
            </fn>
            <fn>
              <p>LMF1 = lipase maturation factor 1</p>
            </fn>
            <fn>
              <p>LPL = lipoprotein lipase</p>
            </fn>
            <fn id="lpl.TF.2.1">
              <label>1. </label>
              <p>
                <xref ref-type="bibr" rid="lpl.REF.gotoda.2012.1">Gotoda et la [2012]</xref>
              </p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <list list-type="bullet">
          <list-item>
            <p><bold>Familial apolipoprotein C-II (apoC-II) deficiency</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/207750">207750</ext-link>). ApoC-II is a cofactor for LPL. Familial apoC-II deficiency is an extremely rare autosomal recessive disorder that differs from familial LPL deficiency in that (1) symptoms generally develop at a later age (13-60 years) and (2) individuals may develop chronic pancreatic insufficiency with steatorrhea and insulin-dependent diabetes mellitus. The diagnosis is based on the identification of biallelic pathogenic variants in <italic toggle="yes">APOC2</italic>, on assay of plasma apoC-II concentration or activation of a purified LPL standard, and on gel electrophoresis of VLDL apolipoproteins. Infusion of normal plasma into an individual with familial apoC-II deficiency results in dramatic reduction of the plasma triglyceride concentration. Treatment is a low-fat diet throughout life.</p>
          </list-item>
          <list-item>
            <p><bold>Familial apolipoprotein A-V deficiency</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/144650">144650</ext-link>). It has been suggested that apoA-V facilitates the interaction of endothelial heparan sulfate with apoC-II on triglyceride-rich lipoproteins and the interaction of apoC-II with LPL on the vascular endothelium. Several families with apoA-V deficiency have been reported to have severe hypertriglyceridemia. Biallelic large-effect loss-of-function pathogenic variants in <italic toggle="yes">APOA5</italic> can lead to familial chylomicronemia syndrome, while heterozygous carriers are predisposed to hypertriglyceridemia, but often demonstrate a normal clinical and biochemical phenotype in the absence of secondary non-genetic factors.</p>
          </list-item>
          <list-item>
            <p><bold>Familial lipase maturation factor 1 (LMF1) deficiency</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/246650">246650</ext-link>). LMF1 is a transmembrane protein localized to the endoplasmic reticulum involved in the maturation of both LPL and hepatic lipase (HL). One affected individual, homozygous for a biallelic <italic toggle="yes">LMF1</italic> pathogenic variant, had very low LPL activity, modestly low HL activity, and chylomicronemia [<xref ref-type="bibr" rid="lpl.REF.p_terfy.2007.1483">P&#x000e9;terfy et al 2007</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>Familial glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) deficiency</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/615947">615947</ext-link>). GPIHBP1 appears to be a binding site for LPL on the capillary endothelial surface, perhaps through binding with apoA-V [<xref ref-type="bibr" rid="lpl.REF.beigneux.2007.279">Beigneux et al 2007</xref>]. Several individuals with GPIHBP1 deficiency have been described. Biallelic large-effect loss-of-function variants of <italic toggle="yes">GPIHBP1</italic> can lead to familial chylomicronemia syndrome, while heterozygous carriers are predisposed to hypertriglyceridemia, but often demonstrate a normal clinical and biochemical phenotype in the absence of secondary non-genetic factors. Recently, autoantibodies against GPIHBP1 were shown to cause chylomicronemia syndrome [<xref ref-type="bibr" rid="lpl.REF.beigneux.2017.1647">Beigneux et al 2017</xref>].</p>
          </list-item>
        </list>
      </sec>
      <sec id="lpl.Management">
        <title>Management</title>
        <sec id="lpl.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with familial lipoprotein lipase (LPL) deficiency, measurement of plasma triglyceride concentration is recommended.</p>
          <p>Consultation with a clinical geneticist and/or genetic counselor may also be considered.</p>
        </sec>
        <sec id="lpl.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p><bold>Medical nutrition therapy.</bold> Morbidity and mortality can be prevented by maintaining plasma triglyceride concentration at less than 2000 mg/dL; a good clinical goal is less than 1000 mg/dL [<xref ref-type="bibr" rid="lpl.REF.viljoen.2012.505">Viljoen &#x00026; Wierzbicki 2012</xref>]. Restriction of dietary fat to no more than 20 g/day or 15% of total energy intake is usually sufficient to reduce plasma triglyceride concentration and to keep the individual with familial LPL deficiency free of symptoms.</p>
          <p>Medium-chain triglycerides may be used for cooking, as they are absorbed directly into the portal vein without becoming incorporated into chylomicron triglyceride.</p>
          <p>The success of therapy depends on the individual's acceptance of the fat restriction, including both unsaturated and saturated fat. Note: Fish oil supplements, which are effective in disorders of excess hepatic triglyceride production, are not effective in LPL deficiency and are contraindicated (see <xref ref-type="sec" rid="lpl.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</xref>).</p>
          <p>The enlarged liver and spleen can return to normal size within one week of lowering of triglyceride concentrations.</p>
          <p>The xanthomas can clear over the course of weeks to months. Recurrent or persistent eruptive xanthomas indicate inadequate therapy.</p>
          <p>Pancreatitis associated with the chylomicronemia syndrome is treated in the manner typical for other forms of pancreatitis.</p>
          <list list-type="bullet">
            <list-item>
              <p>Discontinuation of oral fat intake stops chylomicron triglyceride formation, and replacement with hypocaloric parenteral nutrition decreases VLDL triglyceride production.</p>
            </list-item>
            <list-item>
              <p>Administration of excess calories, as in hyperalimentation, is contraindicated in the acute state. The intravenous administration of lipid emulsions may lead to persistent or recurrent pancreatitis.</p>
            </list-item>
          </list>
          <p>If recurrent pancreatitis with severe hypertriglyceridemia occurs, total dietary fat intake needs to be reduced.</p>
        </sec>
        <sec id="lpl.Prevention_of_Primary_Manifestations">
          <title>Prevention of Primary Manifestations</title>
          <p>See <xref ref-type="sec" rid="lpl.Treatment_of_Manifestations">Treatment of Manifestations</xref>.</p>
        </sec>
        <sec id="lpl.Prevention_of_Secondary_Complication">
          <title>Prevention of Secondary Complications</title>
          <p>Prevention of recurrent acute pancreatitis decreases the risk of developing diabetes mellitus. Fat malabsorption is very rare.</p>
        </sec>
        <sec id="lpl.Surveillance">
          <title>Surveillance</title>
          <p>Plasma triglyceride levels need to be followed over time to evaluate the affected individual&#x02019;s success in following the very low-fat dietary recommendations. When the triglyceride level is above 1000 mg/dL, a fasting sample is not required for this evaluation. Other components of the lipid profile do not need to be routinely measured.</p>
          <p>Affected individuals who develop abdominal pain need to contact their physician.</p>
        </sec>
        <sec id="lpl.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Avoidance of agents known to increase endogenous triglyceride concentration such as alcohol, oral estrogens, diuretics, isotretinoin, glucocorticoids, selective serotonin reuptake inhibitors, and beta-adrenergic blocking agents is recommended.</p>
          <p>Fish oil supplements are contraindicated as they contribute to chylomicron levels.</p>
        </sec>
        <sec id="lpl.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate at-risk sibs during infancy. Early diagnosis and implementation of dietary fat intake restriction can prevent symptoms and related medical complications.</p>
          <p>Evaluations can include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Measurement of plasma triglyceride concentration;</p>
            </list-item>
            <list-item>
              <p>Molecular genetic testing if the pathogenic variants in the family are known.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="lpl.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to evaluation of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="lpl.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>During pregnancy in a woman with LPL deficiency, extreme dietary fat restriction to less than two grams per day during the second and third trimester with close monitoring of plasma triglyceride concentration can result in delivery of a normal infant with normal plasma concentrations of essential fatty acids [<xref ref-type="bibr" rid="lpl.REF.alshali.2002.125">Al-Shali et al 2002</xref>].</p>
          <p>One woman with LPL deficiency delivered a normal child following a one-gram per day fat diet and treatment with gemfibrozil (600 mg/day) [<xref ref-type="bibr" rid="lpl.REF.tsai.2004.27">Tsai et al 2004</xref>]. Despite concerns about the possibility of essential fatty acid deficiency in the newborn, normal essential fatty acids were found in cord blood, as were normal levels of fibrate metabolites.</p>
          <p>See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.mothertobaby.org/">MotherToBaby</ext-link> for further information on medication use during pregnancy.</p>
        </sec>
        <sec id="lpl.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p><italic toggle="yes">LPL</italic> gene therapy is available in Europe and the US for the treatment of familial LPL deficiency. It consists of the <italic toggle="yes">LPL</italic> Ser447Ter variant in an adeno-associated virus serotype 1 (alipogene tiparvovec). Twenty percent of the general population has the Ser447Ter allelic variant, which results in a prematurely truncated LPL that is associated with increased lipolytic function and an anti-atherogenic lipid profile and can therefore be regarded as a naturally occurring gain-of-function variant (reviewed by <xref ref-type="bibr" rid="lpl.REF.gaudet.2013.361">Gaudet et al [2013]</xref>). Note that the standard nomenclature for this variant is <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/protein/NP_000228.1">NP_000228.1</ext-link>:p.Ser474Ter (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000237.2">NM_000237.2</ext-link>:c.1421C&#x0003e;G). Several other targeted therapies are in development or under investigation, including inhibitors of microsomal triglyceride transfer protein (MTP) [<xref ref-type="bibr" rid="lpl.REF.sacks.2014.443">Sacks et al 2014</xref>], diacylglycerol acyl transferase 1 (DGAT1) [<xref ref-type="bibr" rid="lpl.REF.meyers.2015.8">Meyers et al 2015</xref>], apoC-III [<xref ref-type="bibr" rid="lpl.REF.gaudet.2014.2200">Gaudet et al 2014</xref>], and angiopoietin-like protein 3 (ANGPTL3) [<xref ref-type="bibr" rid="lpl.REF.gryn.2015.484">Gryn &#x00026; Hegele 2015</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
        <sec id="lpl.Other">
          <title>Other</title>
          <p>The lipid-lowering drugs that are used to treat other disorders of lipid metabolism are not effective in individuals with familial LPL deficiency.</p>
          <p>Although plasmapheresis and antioxidant therapy have been suggested as treatment for pancreatitis, they do not appear to be needed for either acute therapy or long-term care.</p>
        </sec>
      </sec>
      <sec id="lpl.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="lpl.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Familial LPL deficiency is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="lpl.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected individual are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">LPL</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes are asymptomatic but may have moderately elevated plasma triglyceride concentrations and may be at mild risk for premature atherosclerosis.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes are asymptomatic but may have moderately elevated plasma triglyceride concentrations and may be at mild risk for premature atherosclerosis.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with familial LPL deficiency are obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">LPL</italic>.</p>
          <p><bold>Other family members.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier of an <italic toggle="yes">LPL</italic> pathogenic variant.</p>
        </sec>
        <sec id="lpl.Carrier_Heterozygote_Detection">
          <title>Carrier (Heterozygote) Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">LPL</italic> pathogenic variants in the family. The lipid phenotype of heterozygotes varies widely from completely normal to moderate-to-severe hypertriglyceridemia and cannot be used to predict carrier status.</p>
        </sec>
        <sec id="lpl.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See <xref ref-type="sec" rid="lpl.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
        </sec>
        <sec id="lpl.Prenatal_Testing_and_Preimplantation">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">LPL</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for familial LPL deficiency are possible.</p>
          <p>Differences in perspective may exist among medical professionals and in families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate. In practice, prenatal testing is rarely requested because of the availability of effective treatment.</p>
        </sec>
      </sec>
      <sec id="lpl.Resources">
        <title>Resources</title>
      </sec>
      <sec id="lpl.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">LPL</italic> comprises ten exons; the last one encodes the long untranslated 3&#x02019;-end of the mRNA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000237.2">NM_000237.2</ext-link>). The sequence of <italic toggle="yes">LPL</italic> is highly conserved among mammalian species.</p>
        <p><bold>Pathogenic variants.</bold> More than 220 pathogenic variants have been identified [<xref ref-type="bibr" rid="lpl.REF.brunzell.2001">Brunzell &#x00026; Deeb 2001</xref>, <xref ref-type="bibr" rid="lpl.REF.gilbert.2001.25">Gilbert et al 2001</xref>]; see <related-object source-id="gene" document-id="lpl" object-id="lpl.molgen.TA">Table A</related-object>, <bold>HGMD</bold>. Approximately 70% of these variants are missense, 10% nonsense, and 18% nucleotide insertions and deletions; a few splice site variants are also known. About 3% of pathogenic variants have an exon or multiexon deletion, duplication, insertion, or complex rearrangement.</p>
        <p><bold>Normal gene product.</bold> Lipoprotein lipase (LPL) is a glycoprotein that is synthesized in adipose tissue and cardiac and skeletal muscle, but not in the postpartum liver. It is transported to the luminal surface of the capillary endothelium of extrahepatic tissues. It is essential for the hydrolysis of chylomicron and VLDL triglycerides to provide free fatty acids to tissue for energy production. LPL has two major domains: a larger NH<sub>2</sub>-terminal domain linked by a short region to a COOH-terminal domain of approximately half its size. The globular NH<sub>2</sub>-terminal domain specifies the catalytic properties of the lipase, whereas the COOH-terminal domain specifies substrate specificity and heparin-binding properties. <italic toggle="yes">LPL</italic> encodes a protein of 475 amino acids that becomes a mature protein of 448 residues after cleavage of a signal peptide (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/protein/NP_000228.1">NP_000228.1</ext-link>).</p>
        <p><bold>Abnormal gene product.</bold> Pathogenic deletions and nonsense and splice site variants presumably lead to absent or truncated LPL with defective catalytic activity. Most of the variants are in the highly conserved central homology region [<xref ref-type="bibr" rid="lpl.REF.brunzell.2001">Brunzell &#x00026; Deeb 2001</xref>, <xref ref-type="bibr" rid="lpl.REF.gilbert.2001.25">Gilbert et al 2001</xref>]. Many missense variants result in LPL deficiency secondary to LPL homodimer instability.</p>
      </sec>
      <sec id="lpl.References">
        <title>References</title>
        <sec id="lpl.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="lpl.Literature_Cited.reflist0">
            <ref id="lpl.REF.alshali.2002.125">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Al-Shali</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fellows</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huff</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolfe</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hegele</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Successful pregnancy outcome in a patient with severe chylomicronemia due to compound heterozygosity for mutant lipoprotein lipase.</article-title>
                <source>Clin Biochem</source>
                <volume>35</volume>
                <fpage>125</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">11983347</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.beigneux.2007.279">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beigneux</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davies</surname>
                    <given-names>BS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinstein</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farber</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Qiao</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peale</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bunting</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walzem</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blaner</surname>
                    <given-names>WS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ding</surname>
                    <given-names>ZM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Melford</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wongsiriroj</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shu</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Sauvage</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ryan</surname>
                    <given-names>RO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fong</surname>
                    <given-names>LG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bensadoun</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>SG</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons.</article-title>
                <source>Cell Metab</source>
                <volume>5</volume>
                <fpage>279</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">17403372</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.beigneux.2009.956">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beigneux</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franssen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bensadoun</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Melford</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peter</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walzem</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinstein</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davies</surname>
                    <given-names>BS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuivenhoven</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kastelein</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fong</surname>
                    <given-names>LG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dallinga-Thie</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>SG</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase.</article-title>
                <source>Arterioscler. Thromb. Vasc. Biol</source>
                <volume>29</volume>
                <fpage>956</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">19304573</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.beigneux.2017.1647">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beigneux</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyashita</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ploug</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blom</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ai</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linton</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khovidhunkit</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dufour</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McMahon</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pullinger</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sandoval</surname>
                    <given-names>NP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hu</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allan</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larsson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Machida</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murakami</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reue</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tontonoz</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldberg</surname>
                    <given-names>IJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moulin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charri&#x000e8;re</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fong</surname>
                    <given-names>LG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakajima</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>SG</given-names>
                  </name>
                </person-group>
                <year>2017</year>
                <article-title>Autoantibodies against GPIHBP1 as a cause of hypertriglyceridemia.</article-title>
                <source>N Engl J Med</source>
                <volume>376</volume>
                <fpage>1647</fpage>
                <lpage>58</lpage>
                <pub-id pub-id-type="pmid">28402248</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.brahm.2015.352">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brahm</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hegele</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>Chylomicronaemia&#x02013;current diagnosis and future therapies.</article-title>
                <source>Nat Rev Endocrinol</source>
                <volume>11</volume>
                <fpage>352</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">25732519</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.brunzell.2001">
              <mixed-citation publication-type="book">Brunzell JD, Deeb SS. Familial lipoprotein lipase deficiency, apo CII deficiency and hepatic lipase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. <italic toggle="yes">The Metabolic and Molecular Bases of Inherited Disease.</italic> 8 ed. New York, NY: McGraw-Hill; 2001:2789-816</mixed-citation>
            </ref>
            <ref id="lpl.REF.calandra.2006.122">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Calandra</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Priore Oliva</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tarugi</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertolini</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency.</article-title>
                <source>Curr. Opin. Lipidol</source>
                <volume>17</volume>
                <fpage>122</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16531747</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.chait.1983.209">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chait</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunzell</surname>
                    <given-names>JD</given-names>
                  </name>
                </person-group>
                <year>1983</year>
                <article-title>Severe hypertriglyceridemia: role of familial and acquired disorders.</article-title>
                <source>Metabolism</source>
                <volume>32</volume>
                <fpage>209</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">6827992</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.chait.1981.343">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chait</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robertson</surname>
                    <given-names>HT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunzell</surname>
                    <given-names>JD</given-names>
                  </name>
                </person-group>
                <year>1981</year>
                <article-title>Chylomicronemia syndrome in diabetes mellitus.</article-title>
                <source>Diabetes Care</source>
                <volume>4</volume>
                <fpage>343</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">7344882</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.gaudet.2014.2200">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gaudet</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brisson</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tremblay</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alexander</surname>
                    <given-names>VJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singleton</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geary</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baker</surname>
                    <given-names>BF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crooke</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Witztum</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Targeting APOC3 in the familial chylomicronemia syndrome.</article-title>
                <source>N Engl J Med</source>
                <volume>371</volume>
                <fpage>2200</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">25470695</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.gaudet.2013.361">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gaudet</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000e9;thot</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x000e9;ry</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brisson</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Essiembre</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tremblay</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tremblay</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Wal</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Twisk</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Bulk</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sier-Ferreira</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Deventer</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial.</article-title>
                <source>Gene Ther</source>
                <volume>20</volume>
                <fpage>361</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22717743</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.gilbert.2001.25">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gilbert</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouis</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griglio</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Lumley</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laplaud</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gilbert</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouis</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griglio</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Lumley</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laplaud</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Lipoprotein lipase (LPL) deficiency: a new patient homozygote for the preponderant mutation Gly188Glu in the human LPL gene and review of reported mutations: 75% are clustered in exons 5 and 6.</article-title>
                <source>Ann Genet</source>
                <volume>44</volume>
                <fpage>25</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">11334614</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.gin.2012.2961">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goulbourne</surname>
                    <given-names>CN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adeyo</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beigneux</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davies</surname>
                    <given-names>BS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tat</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voss</surname>
                    <given-names>CV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bensadoun</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fong</surname>
                    <given-names>LG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>SG</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Chylomicronemia mutations yield new insights into interactions between lipoprotein lipase and GPIHBP1.</article-title>
                <source>Hum Mol Genet</source>
                <volume>21</volume>
                <fpage>2961</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">22493000</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.gotoda.2012.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gotoda</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shirai</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohta</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kobayashi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yokoyama</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oikawa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bujo</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishibashi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arai</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamashita</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harada-Shiba</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sone</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamada</surname>
                    <given-names>N</given-names>
                  </name>
                  <etal/>
                </person-group>
                <year>2012</year>
                <article-title>Diagnosis and management of type I and type V hyperlipoproteinemia.</article-title>
                <source>J Atheroscler Thromb</source>
                <volume>19</volume>
                <fpage>1</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">22129523</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.gryn.2015.484">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gryn</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hegele</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>Novel therapeutics in hypertriglyceridemia.</article-title>
                <source>Curr Opin Lipidol</source>
                <volume>26</volume>
                <fpage>484</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">26780002</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.hegele.2014.655">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hegele</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ginsberg</surname>
                    <given-names>HN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chapman</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nordestgaard</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuivenhoven</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Averna</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bor&#x000e9;n</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruckert</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Catapano</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Descamps</surname>
                    <given-names>OS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hovingh</surname>
                    <given-names>GK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Humphries</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kovanen</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masana</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pajukanta</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parhofer</surname>
                    <given-names>KG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raal</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ray</surname>
                    <given-names>KK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santos</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stalenhoef</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stroes</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taskinen</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tybj&#x000e6;rg-Hansen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watts</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiklund</surname>
                    <given-names>O</given-names>
                  </name>
                  <etal/>
                </person-group>
                <year>2014</year>
                <article-title>The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.</article-title>
                <source>Lancet Diabetes Endocrinol.</source>
                <year>2014</year>
                <volume>2</volume>
                <fpage>655</fpage>
                <lpage>66</lpage>
                <pub-id pub-id-type="pmid">24731657</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.heilman.1974.67">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Heilman</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fisher</surname>
                    <given-names>WR</given-names>
                  </name>
                </person-group>
                <year>1974</year>
                <article-title>Hyperlipidemic dementia.</article-title>
                <source>Arch Neurol</source>
                <volume>31</volume>
                <fpage>67</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">4834546</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.jap.2003.122">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jap</surname>
                    <given-names>TS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jenq</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>YC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiu</surname>
                    <given-names>CY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheng</surname>
                    <given-names>HM</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Mutations in the lipoprotein lipase gene as a cause of hypertriglyceridemia and pancreatitis in Taiwan.</article-title>
                <source>Pancreas</source>
                <volume>27</volume>
                <fpage>122</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12883259</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.kawashiri.2005.6541">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kawashiri</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Higashikata</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizuno</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takata</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katsuda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miwa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nozue</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nohara</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inazu</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kobayashi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koizumi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mabuchi</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Long-term course of lipoprotein lipase (LPL) deficiency due to homozygous LPL(Arita) in a patient with recurrent pancreatitis, retained glucose tolerance, and atherosclerosis.</article-title>
                <source>J Clin Endocrinol Metab</source>
                <volume>90</volume>
                <fpage>6541</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">16174715</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.mart_ncampos.2014.61">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mart&#x000ed;n-Campos</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Julve</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roig</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;nez</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Errico</surname>
                    <given-names>TL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;nez-Couselo</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Escol&#x000e0;-Gil</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000e9;ndez-Gonz&#x000e1;lez</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blanco-Vaca</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Molecular analysis of chylomicronemia in a clinical laboratory setting: diagnosis of 13 cases of lipoprotein lipase deficiency.</article-title>
                <source>Clin Chim Acta</source>
                <volume>429</volume>
                <fpage>61</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">24291057</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.meyers.2015.8">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Meyers</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tremblay</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jiang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaudet</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome.</article-title>
                <source>Lipids Health Dis</source>
                <volume>14</volume>
                <fpage>8</fpage>
                <pub-id pub-id-type="pmid">25889044</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.murthy.1996.101">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Murthy</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Julien</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gagne</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Molecular pathobiology of the human lipoprotein lipase gene.</article-title>
                <source>Pharmacol Ther</source>
                <volume>70</volume>
                <fpage>101</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">8843465</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.nilsson.2011.15">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nilsson</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heeren</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olivecrona</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merkel</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Apolipoprotein A-V; a potent triglyceride reducer.</article-title>
                <source>Atherosclerosis</source>
                <volume>219</volume>
                <fpage>15</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">21831376</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.okubo.2015.148">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Okubo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toromanovic</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ebara</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murase</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>Apolipoprotein C-II: a novel large deletion in APOC2 caused by Alu&#x02013;Alu homologous recombination in an infant with apolipoprotein C-II deficiency.</article-title>
                <source>Clin Chim Acta</source>
                <volume>438</volume>
                <fpage>148</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">25172036</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.p_terfy.2012.790">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>P&#x000e9;terfy</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Lipase maturation factor 1: a lipase chaperone involved in lipid metabolism.</article-title>
                <source>Biochim Biophys Acta</source>
                <volume>1821</volume>
                <fpage>790</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">22063272</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.p_terfy.2007.1483">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>P&#x000e9;terfy</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben-Zeev</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mao</surname>
                    <given-names>HZ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weissglas-Volkov</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aouizerat</surname>
                    <given-names>BE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pullinger</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frost</surname>
                    <given-names>PH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kane</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malloy</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reue</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pajukanta</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doolittle</surname>
                    <given-names>MH</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia.</article-title>
                <source>Nat Genet</source>
                <volume>39</volume>
                <fpage>1483</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">17994020</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.sacks.2014.443">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sacks</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanesa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hegele</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide.</article-title>
                <source>JAMA Intern Med</source>
                <volume>174</volume>
                <fpage>443</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">24366202</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.stroes.2017.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stroes</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moulin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parhofer</surname>
                    <given-names>KG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rebours</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>L&#x004e7;hr</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Averna</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2017</year>
                <article-title>Diagnostic algorithm for familial chylomicronemia syndrome.</article-title>
                <source>Atheroscler Suppl</source>
                <volume>23</volume>
                <fpage>1</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">27998715</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.tsai.2004.27">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tsai</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Veldee</surname>
                    <given-names>MY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chait</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunzell</surname>
                    <given-names>JD</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Potential of essential fatty acid deficiency with extremely low fat diet in lipoprotein lipase deficiency during pregnancy: A case report.</article-title>
                <source>BMC Pregnancy Childbirth</source>
                <volume>4</volume>
                <fpage>27</fpage>
                <pub-id pub-id-type="pmid">15610556</pub-id>
              </element-citation>
            </ref>
            <ref id="lpl.REF.viljoen.2012.505">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Viljoen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wierzbicki</surname>
                    <given-names>AS</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Diagnosis and treatment of severe hypertriglyceridemia.</article-title>
                <source>Expert Rev Cardiovasc Ther</source>
                <volume>10</volume>
                <fpage>505</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">22458582</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="lpl.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="lpl.Author_History">
          <title>Author History</title>
          <p>John D Brunzell, MD; University of Washington (1999-2017)John R Burnett, MB ChB, MD, PhD, FRCPA (2017-present)Robert A Hegele, MD, FRCPC, FACP (2017-present)Amanda J Hooper, PhD (2017-present)</p>
        </sec>
        <sec id="lpl.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>22 June 2017 (ma) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>15 December 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>28 July 2009 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>1 October 2007 (cd) Revision: deletion/duplication analysis available; prenatal testing available; mutation analysis for p.Gly188Glu done by sequence analysis</p>
            </list-item>
            <list-item>
              <p>24 April 2006 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>9 April 2004 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>18 February 2002 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>12 October 1999 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>April 1999 (jb) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
